Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it

Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.